Serving the Society Since 1986
Advanced Search
Volume 39 Issue 6
December 2024
    Citation: Feixia Gao, Qi Wang, Chenchen Qiu, Jian Luo, Xiuling Li. Pandemic preparedness of effective vaccines for the outbreak of newly H5N1 highly pathogenic avian influenza virus .VIROLOGICA SINICA, 2024, 39(6) : 981-985.  http://dx.doi.org/10.1016/j.virs.2024.11.005
    shu

    Pandemic preparedness of effective vaccines for the outbreak of newly H5N1 highly pathogenic avian influenza virus

    cstr: 32224.14.j.virs.2024.11.005

    • a. Shanghai Institute of Biological Products, 200052, Shanghai, China;

    • b. State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Beijing, China

    • Highlights
      1. Analyzed the outbreak situation and viral characteristics of the newly H5N1 highly pathogenic avian influenza (HPAI) virus.
      2. The current approval and research and development of the H5N1 HPAI vaccines were summarized.
      3. Proposed vaccine development approaches against newly H5N1 virus, e.g. adjuvanted vaccine, mRNA vaccine, multivalent vaccine.
      4. Discussed other prevention and control strategies, e.g. poultry vaccination, global surveillance and comprehensive testing.
    • 加载中

      1. Alasiri, A., Soltane, R., Hegazy, A., Khalil, A.M., Mahmoud, S.H., Khalil, A.A., Martinez-Sobrido, L., Mostafa, A., 2023. Vaccination and antiviral treatment against avian influenza H5Nx viruses: a harbinger of virus control or evolution. Vaccines 11, 1628.

      2. Cargnin Faccin, F., Perez, D.R., 2024. Pandemic preparedness through vaccine development for avian influenza viruses. Hum. Vaccines Immunother. 20, 2347019.

      3. Fan, S., Deng, G., Song, J., Tian, G., Suo, Y., Jiang, Y., Guan, Y., Bu, Z., Kawaoka, Y., Chen, H., 2009. Two amino acid residues in the 253 matrix protein m1 contribute to the virulence difference of H5N1 avian influenza viruses in mice. Virology, 384, 28-32.

      4. Furey, C., Scher, G., Ye, N., Kercher, L., Debeauchamp, J., Crumpton, J.C., Jeevan, T., Patton, C., Franks, J., Rubrum, A., Alameh, M., Fan, S.H.Y., Phan, A.T., Hunter, C.A., Webby, R.J., Weissman, D., Hensley, S.E., 2024. Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nat. Commun., 15, 4350.

      5. Gao, F., Liu, X., Dang, Y., Duan, P., Xu, W., Zhang, X., Wang, S., Luo, J., Li, X., 2022. Addavax-adjuvanted H5N8 inactivated vaccine induces robust humoral immune response against different clades of H5 viruses. Vaccines, 10, 1683.

      6. Jiao, P., Tian, G., Li, Y., Deng, G., Jiang, Y., Liu, C., Liu, W., Bu, Z., Kawaoka, Y., Chen, H., 2008. A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J. Virol., 82, 1146-1154.

      7. Kayali, G., Kandeil, A., El-Shesheny, R., Kayed, A.S., Maatouq, A.M., Cai, Z., Mckenzie, P.P., Webby, R. J., El Refaey, S., Kandeel, A., Ali, M.A., 2016. Avian influenza a(H5N1) virus in Egypt. Emerg. Infect. Dis., 22, 379-388.

      8. Khurana, S., King, L.R., Manischewitz, J., Posadas, O., Mishra, A.K., Liu, D., Beigel, J.H., Rappuoli, R., Tsang, J.S., Golding, H., 2024. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nat. Med., 30, 2771-2776.

      9. Sakai-Tagawa, Y., Horimoto, T., Skehel, J. J., Shinya, K., Yamada, S., Nidom, C. A., Gamblin, S. J., Hay, A., Russell, R. J., Kawaoka, Y., Lin, Y., Ito, M., Stevens, D. J., Suzuki, T., Kiso, M., Murata, T., Suzuki, Y., Kiso, M., Haire, L. F., Le, M. Q., Muramoto, Y., Usui, T., Sawada, T., 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza a viruses to human-type receptors. Nature, 7117, 378-382.

      10. Shi, J., Zeng, X., Cui, P., Yan, C., Chen, H., 2023. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies. Emerg. Microb. Infect., 12, 2155072.

      11. Siegers, J.Y., Xie, R., Byrne, A.M.P., Edwards, K.M., Hu, S., Yann, S., Sin, S., Tok, S., Chea, K., Horm, S., Rith, C., Keo, S., Pum, L., Duong, V., Auerswald, H., Phou, Y., Kol, S., Spiegel, A., Harvey, R., Tum, S., Sorn, S., Seng, B., Sengdoeurn, Y., Darapheak, C., Savuth, C., Hak, M., Ieng, V., Patel, S., Di, H., Davis, C.T., Finlay, A., Sar, B., Thielen, P., Claes, F.F., Lewis, N.S., Sovann, L., Dhanasekaran, V., Karlsson, E.A., 2024. Emergence of a novel reassortant clade 2.3.2.1c avian influenza a/H5N1 virus associated with human cases in Cambodia. medRxiv, 2024.11.04.24313747.

      12. Uyeki, T.M., Milton, S., Abdul Hamid, C., Reinoso Webb, C., Presley, S.M., Shetty, V., Rollo, S.N., Martinez, D.L., Rai, S., Gonzales, E.R., Kniss, K.L., Jang, Y., Frederick, J.C., De La Cruz, J.A., Liddell, J., Di, H., Kirby, M.K., Barnes, J.R., Davis, C.T., 2024. Highly pathogenic avian influenza a(H5N1) virus infection in a dairy farm worker. N. Engl. J. Med., 21, 2028-2029.

      13. Zeng, X., He, X., Meng, F., Qi, M., Wang, Y., Bao, H., Liu, Y., Deng, G., Shi, J., Li, Y., Tian, G., Chen, H., 2022. Protective efficacy of an H5/H7 trivalent inactivated vaccine (H5-Re13, H5-Re14, and H7-Re4 strains) in chickens, ducks, and geese against newly detected H5N1, H5N6, H5N8, and H7N9 viruses. J. Integr. Agric., 21, 2086-2094.

      14. Zhang, Y., Cui, P., Shi, J., Zeng, X., Jiang, Y., Chen, Y., Zhang, J., Wang, C., Wang, Y., Tian, G., Chen, H., Kong, H., Deng, G., 2024. A broad-spectrum vaccine candidate against H5 viruses bearing different sub-clade 2.3.4.4 HA genes. Npj Vacc., 1, 152.

      15. Zhu, W., Li, X., Dong, J., Bo, H., Liu, J., Yang, J., Zhang, Y., Wei, H., Huang, W., Zhao, X., Chen, T., Yang, J., Li, Z., Zeng, X., Li, C., Tang, J., Xin, L., Gao, R., Liu, L., Tan, M., Shu, Y., Yang, L., Wang, D., 2022. Epidemiologic, clinical, and genetic characteristics of human infections with influenza A(H5N6) viruses, China. Emerg. Infect. Dis. 7, 1332-1344.

    • 加载中

    Figures(1)

    PDF

    Article Metrics

    Article views(2681) PDF downloads(13) Cited by()

    Related
    Proportional views

      Pandemic preparedness of effective vaccines for the outbreak of newly H5N1 highly pathogenic avian influenza virus

        Corresponding author: Jian Luo, rojjer2009@hotmail.com
        Corresponding author: Xiuling Li, 18910222351@163.com
      • a. Shanghai Institute of Biological Products, 200052, Shanghai, China;
      • b. State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Beijing, China
      • Received Date: 01 October 2024
      • Accepted Date: 28 November 2024

      Abstract: Highlights
      1. Analyzed the outbreak situation and viral characteristics of the newly H5N1 highly pathogenic avian influenza (HPAI) virus.
      2. The current approval and research and development of the H5N1 HPAI vaccines were summarized.
      3. Proposed vaccine development approaches against newly H5N1 virus, e.g. adjuvanted vaccine, mRNA vaccine, multivalent vaccine.
      4. Discussed other prevention and control strategies, e.g. poultry vaccination, global surveillance and comprehensive testing.

        HTML

      Figure (1)  Reference (15) Relative (20)

      目录

      This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return